DNL343 - An Overview
The demo fulfilled its primary endpoint by demonstrating that in people with NASH and moderate to reasonable fibrosis all regimens were being very well tolerated. The commonest adverse events (AEs) were gastrointestinal. Small pruritus (itching) was noticed in men and women handled with cilofexor. Throughout all teams, 5–fourteen% of men and wome